Cargando…
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary moveme...
Autores principales: | Bandopadhyay, Ritam, Mishra, Nainshi, Rana, Ruhi, Kaur, Gagandeep, Ghoneim, Mohammed M., Alshehri, Sultan, Mustafa, Gulam, Ahmad, Javed, Alhakamy, Nabil. A., Mishra, Awanish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021725/ https://www.ncbi.nlm.nih.gov/pubmed/35462934 http://dx.doi.org/10.3389/fphar.2022.805388 |
Ejemplares similares
-
DNA Methylation: A Promising Approach in Management of Alzheimer’s Disease and Other Neurodegenerative Disorders
por: Kaur, Gagandeep, et al.
Publicado: (2022) -
Recent Developments in Diagnosis of Epilepsy: Scope of MicroRNA and Technological Advancements
por: Bandopadhyay, Ritam, et al.
Publicado: (2021) -
“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016) -
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013) -
Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)